Author | Correa, Rodrigo de Souza | |
Author | Freire, Vitória | |
Author | Barbosa, Marília Imaculada Frazão | |
Author | Bezerra, Daniel Pereira | |
Author | Bomfim, Larissa M | |
Author | Moreira, Diogo Rodrigo de Magalhães | |
Author | Soares, Milena Botelho Pereira | |
Author | Ellena, Javier Alcides | |
Author | Batista, Alzir Azevedo | |
Access date | 2019-02-15T17:19:06Z | |
Available date | 2019-02-15T17:19:06Z | |
Document date | 2018 | |
Citation | CORREA, R. S. et al. Ru (II)–thyminate complexes new metallodrug candidates against tumor cells. New Journal of Chemistry, v. 42, p. 6794-6802, 2018. | pt_BR |
ISSN | 1144-0546 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/31690 | |
Sponsorship | Research Council CNPq,
FAPEMIG, FAPESB and FAPESP. R. S. Correa would like to
thank CNPq for financial support (project 403588/2016-2 and
308370/2017-1). | pt_BR |
Language | eng | pt_BR |
Publisher | Royal Society of Chemistry | pt_BR |
Rights | restricted access | pt_BR |
Subject in Portuguese | Rutenio | pt_BR |
Subject in Portuguese | Células tumorais | pt_BR |
Subject in Portuguese | Testes de medicamentos anticâncer | pt_BR |
Subject in Portuguese | Anticancerígenos | pt_BR |
Subject in Portuguese | Humanos | pt_BR |
Title | Ru (II)–thyminate complexes new metallodrug candidates against tumor cells | pt_BR |
Type | Article | pt_BR |
Abstract | Herein, we used thymine (HThy) as a ligand to form two new ruthenium(II) complexes with formula
[Ru(PPh3)2(Thy)(bipy)]PF6 (1) and [Ru(Thy)(bipy)(dppb)]PF6 (2). The complexes were characterized by
spectroscopic, spectrometric and X-ray crystallography analyses. Complexes 1 and 2 can interact with
ctDNA presenting binding constants, Kb, of 0.4 and 1.2 103 M 1, respectively. Their cytotoxic activities
towards tumor cell lines (B16-F10, HepG2, K562 and HL-60) and non-tumor cells (PBMCs) were
evaluated using the Alamar blue assay. Complex 1 exhibits high cytotoxicity against tumor cells, showing
IC50 values of 0.01 and 1.81 mM against the HL-60 and HepG2 cell lines, respectively. Therefore,
compound 1 can be considered as a promising antitumor metallodrug. | pt_BR |
Affilliation | Universidade Federal de São Carlos. Departamento de Química. São Carlos, SP, Brasil / Universidade Federal de Ouro Preto. Departamento de Quıímica. Ouro Preto, MG, Brasil. | pt_BR |
Affilliation | Universidade Federal de São Carlos. Departamento de Química. São Carlos, SP, Brasil. | pt_BR |
Affilliation | Universidade Federal de Alfenas. Instituto de Química. Alfenas, MG, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil. | pt_BR |
Affilliation | Universidade de São Paulo. Instituto de Física de São Carlos. Departamento de Física e Informática. São Carlos, SP, Brasil. | pt_BR |
Affilliation | Universidade Federal de São Carlos. Departamento de Química. São Carlos, SP, Brasil. | pt_BR |
Subject | Ruthenium | pt_BR |
Subject | Tumor cell | pt_BR |
Subject | Drug Screening Assays, Antitumor | pt_BR |
Subject | Anticarcinogenic | pt_BR |
Subject | Humans | pt_BR |